MU inventors have identified a drug therapy combining Estrogen Receptor Beta (ERb) ligand with Beta-3 Adrenergic (B3A) ligand to reduce fat (especially in visceral adipose tissue), improve insulin sensitivity, and enhance systemic glucose tolerance.
Approximately 42% of individuals in the United States are obese. Obesity-related conditions are among the most preventable causes of death, including metabolic diseases like diabetes. Factors such as social determinants, genetics, and lifestyle, play a role in the development of these conditions, making them difficult to combat. Most solutions on the present market suggest diet modifications or increased physical activity.
MU inventors have demonstrated combination therapy using ERb and B3A ligands results in a synergistic effect in adipose tissue. B3A activation directly increases ERb density in adipocytes, which in turn enhances fat cell metabolism, resulting in fat loss targeting visceral adipose tissue. In addition to reducing body-fat, this combination therapy can improve insulin sensitivity and enhance systemic glucose tolerance in individuals suffering from metabolic disorders.
– Obesity therapy targeting visceral adipose tissue
– Diabetes therapy targeting blood sugar levels and insulin sensitivity
– Supplement to patient-initiated treatments (i.e. diet modification, exercise)
– Decrease medical costs associated with chronic metabolic diseases
Victoria Vieira-Potter, Dennis Lubahn, Eric Queathem
Queathem et al. Suppression of estrogen receptor beta classical genomic activity enhances systemic and adipose-specific response to chronic beta-3 adrenergic receptor (β3AR) stimulation. Front. Physiol. 13:920675. doi: 10.3389/fphys.2022.92065
Brian Buntaine, MS, MBA
Senior Manager, Technology Transfer
Email: email@example.com TagsNone Posted DateSep 22, 2022 2:06 AM
Name: Brian Buntaine, MS, MBA
Title: Senior Manager, Technology Transfer
Department: MU Technology Advancement Office
Address: Columbia, Missouri 65211